Change search
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf
Virus-Based Immunotherapy of Glioblastoma
Uppsala University, Science for Life Laboratory, SciLifeLab. Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Faculty of Medicine, Department of Immunology, Genetics and Pathology.
Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Faculty of Medicine, Department of Immunology, Genetics and Pathology, Clinical Immunology. Uppsala University, Science for Life Laboratory, SciLifeLab.ORCID iD: 0000-0002-9725-0422
2019 (English)In: Cancers, ISSN 2072-6694, Vol. 11, no 2, article id 186Article, review/survey (Refereed) Published
Abstract [en]

Glioblastoma (GBM) is the most common type of primary brain tumor in adults. Despite recent advances in cancer therapy, including the breakthrough of immunotherapy, the prognosis of GBM patients remains dismal. One of the new promising ways to therapeutically tackle the immunosuppressive GBM microenvironment is the use of engineered viruses that kill tumor cells via direct oncolysis and via stimulation of antitumor immune responses. In this review, we focus on recently published results of phase I/II clinical trials with different oncolytic viruses and the new interesting findings in preclinical models. From syngeneic preclinical GBM models, it seems evident that oncolytic virus-mediated destruction of GBM tissue coupled with strong adjuvant effect, provided by the robust stimulation of innate antiviral immune responses and adaptive anti-tumor T cell responses, can be harnessed as potent immunotherapy against GBM. Although clinical testing of oncolytic viruses against GBM is at an early stage, the promising results from these trials give hope for the effective treatment of GBM in the near future.

Place, publisher, year, edition, pages
2019. Vol. 11, no 2, article id 186
Keywords [en]
oncolytic virotherapy, cancer immunotherapy, glioblastoma
National Category
Neurology
Identifiers
URN: urn:nbn:se:uu:diva-380671DOI: 10.3390/cancers11020186ISI: 000460747200060PubMedID: 30764570OAI: oai:DiVA.org:uu-380671DiVA, id: diva2:1300960
Funder
Swedish Research Council, 2015-03688Swedish Childhood Cancer Foundation, PR2015-0049Swedish Cancer Society, CAN 2016/318Available from: 2019-04-01 Created: 2019-04-01 Last updated: 2019-04-01Bibliographically approved

Open Access in DiVA

fulltext(2614 kB)29 downloads
File information
File name FULLTEXT01.pdfFile size 2614 kBChecksum SHA-512
943dea83620a407728cdddde8b8fca6b6497f0978a005329612ed70c5e91fd5c4d9f4bc61a9ccf9ebf6ca212780023b9f55a975fb09d90e14329da48352cc1e8
Type fulltextMimetype application/pdf

Other links

Publisher's full textPubMed

Search in DiVA

By author/editor
Martikainen, MiikaEssand, Magnus
By organisation
Science for Life Laboratory, SciLifeLabDepartment of Immunology, Genetics and PathologyClinical Immunology
In the same journal
Cancers
Neurology

Search outside of DiVA

GoogleGoogle Scholar
Total: 29 downloads
The number of downloads is the sum of all downloads of full texts. It may include eg previous versions that are now no longer available

doi
pubmed
urn-nbn

Altmetric score

doi
pubmed
urn-nbn
Total: 30 hits
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf